No single lab test can diagnose dementia. Instead, doctors use a combination of blood tests, brain imaging, cognitive assessments, and sometimes spinal fluid analysis to rule out treatable causes of memory loss and identify the type of dementia involved. The process is one of elimination as much as confirmation, because many reversible conditions, from thyroid problems to vitamin deficiencies, can mimic dementia symptoms.
Blood Tests That Rule Out Other Causes
The first round of testing is usually bloodwork, and its main purpose is to check whether something fixable is causing the cognitive problems. These tests don’t detect dementia directly, but they eliminate conditions that can look remarkably similar.
A standard panel typically includes thyroid function tests, since both an underactive and overactive thyroid can cause confusion, slowed thinking, and memory trouble. Vitamin B12 levels are checked because a deficiency causes neurological symptoms that overlap heavily with early dementia. A complete blood count looks for anemia or signs of infection. A basic metabolic panel checks kidney and liver function, blood sugar, and electrolyte levels, all of which can affect cognition when out of balance.
Doctors also commonly test for diabetes (via fasting glucose or hemoglobin A1C), since poorly controlled blood sugar damages blood vessels in the brain over time and contributes to vascular dementia. Depending on the person’s history, screening for syphilis, HIV, or Lyme disease may be included, as these infections can cause cognitive decline if untreated. Testing for heavy metal exposure or certain medications that impair thinking may also be part of the workup.
If all of these come back normal, the cognitive symptoms are more likely caused by a neurodegenerative condition rather than a reversible medical problem.
Cognitive and Neuropsychological Testing
Cognitive screening is one of the most important diagnostic tools and happens in the doctor’s office, not a lab. These structured tests measure memory, attention, language, problem-solving, and spatial awareness to determine how severe the impairment is and which brain functions are most affected.
Short screening tools like the Mini-Mental State Examination (MMSE) or the Montreal Cognitive Assessment (MoCA) take about 10 to 15 minutes. They involve tasks like remembering a short list of words, drawing a clock face, counting backward, or naming animals. The MoCA is generally more sensitive at catching mild cognitive impairment, which is the stage before full dementia. A score below 26 out of 30 on the MoCA typically flags a problem worth investigating further.
For a more detailed picture, a neuropsychologist may conduct a full battery of tests lasting two to four hours. This deeper evaluation helps distinguish between types of dementia. Alzheimer’s disease, for example, tends to hit short-term memory earliest, while frontotemporal dementia often shows up first as personality changes or language difficulties. The pattern of strengths and weaknesses across different cognitive domains helps point toward the right diagnosis.
Brain Imaging
Structural brain scans show whether the brain has shrunk in specific areas, which helps confirm dementia and narrow down its type. An MRI is the preferred option because it provides detailed images of brain tissue. It can reveal shrinkage of the hippocampus (the brain’s memory center), which is a hallmark of Alzheimer’s disease, or show evidence of small strokes that point to vascular dementia. A CT scan is sometimes used instead when an MRI isn’t available or the person can’t tolerate one.
Functional imaging goes a step further by showing how the brain is working, not just what it looks like. A PET scan using a radioactive glucose tracer highlights areas where brain cells have become less active. In Alzheimer’s disease, reduced activity typically appears in the temporal and parietal regions. A newer type of PET scan can detect amyloid plaques, the abnormal protein deposits that define Alzheimer’s, directly in a living person’s brain. Amyloid PET scans are increasingly used when the diagnosis is uncertain, though they’re expensive and not always covered by insurance.
Another PET tracer can detect tau tangles, the second hallmark protein of Alzheimer’s. Tau PET is currently used more in research settings, but it’s becoming part of clinical practice for complex cases where the standard workup hasn’t produced a clear answer.
Spinal Fluid Analysis
A lumbar puncture (spinal tap) collects cerebrospinal fluid, the liquid that surrounds the brain and spinal cord. This fluid contains measurable levels of the proteins associated with Alzheimer’s disease. In people with Alzheimer’s, amyloid protein levels in spinal fluid drop (because the protein is getting trapped in plaques in the brain instead of flowing freely), while tau protein levels rise.
This test is particularly useful when symptoms are atypical, when the person is younger than 65, or when imaging results are inconclusive. It’s a more invasive procedure than a blood draw, involving a needle in the lower back, but it’s generally safe and takes about 30 minutes. Some people experience a headache afterward that resolves within a day or two.
Spinal fluid testing has been a reliable research tool for years and is now used routinely in specialty memory clinics, especially in Europe. In the United States, it’s more commonly ordered by neurologists and dementia specialists than by primary care doctors.
Blood-Based Biomarker Tests
A major recent development is the emergence of blood tests that can detect Alzheimer’s-specific proteins directly. These tests measure phosphorylated tau (p-tau) levels in the blood, which reflect what’s happening in the brain with surprising accuracy. A blood test called p-tau217 has shown accuracy above 90% in identifying Alzheimer’s pathology in research studies, performing nearly as well as spinal fluid analysis or PET scans at a fraction of the cost.
The FDA cleared the first blood-based Alzheimer’s diagnostic test in early 2023, and several others are in the pipeline. These tests are beginning to appear in clinical practice, though they’re not yet standard everywhere. They represent a significant shift because they could eventually replace the need for expensive PET scans or invasive spinal taps in many cases. If your doctor hasn’t mentioned these, it may be worth asking whether a blood biomarker test is appropriate for your situation.
Genetic Testing
Genetic tests aren’t used to diagnose dementia in most cases, but they play a role in specific situations. The APOE gene has a variant called APOE e4 that significantly increases Alzheimer’s risk. Carrying one copy roughly triples the risk, and carrying two copies increases it roughly twelvefold. However, many people with the e4 variant never develop Alzheimer’s, and many people with Alzheimer’s don’t carry it, so the test isn’t diagnostic on its own.
Genetic testing is more directly useful when dementia runs strongly in a family, especially when it appears before age 60. Mutations in three genes (APP, PSEN1, and PSEN2) cause a rare inherited form of Alzheimer’s that accounts for less than 1% of all cases. Finding one of these mutations is essentially a confirmation of the diagnosis.
How the Pieces Fit Together
Diagnosing dementia is not about any single test producing a definitive result. It’s a process that layers evidence: bloodwork eliminates reversible causes, cognitive testing quantifies the impairment, imaging reveals structural or functional brain changes, and biomarker tests identify the specific proteins involved. A skilled clinician synthesizes all of this alongside the person’s medical history, the timeline of symptom progression, and input from family members who’ve observed the changes firsthand.
The full workup can take several weeks from start to finish, sometimes longer if specialty referrals or advanced imaging are needed. If you’re preparing for this process, keeping a written log of the symptoms you’ve noticed, when they started, and how they’ve changed over time gives the doctor valuable information that no lab test can capture.